Literature DB >> 8620420

Serum acute phase reactants and prognosis in renal cell carcinoma.

B Ljungberg1, K Grankvist, T Rasmuson.   

Abstract

BACKGROUND: Inflammatory parameters as acute phase proteins commonly are elevated in patients with renal cell carcinoma. Some of these acute phase reactants have been proposed to influence survival.
METHODS: In 170 patients with renal cell carcinoma, the authors studied six acute phase reactant parameters (erythrocyte sedimentation rate [ESR], C-reactive protein, haptoglobin, ferritin, orosomucoid, and alpha 1-antitrypsin) that were compared with stage and grade.
RESULTS: The acute phase reactants correlated well with each other and with stage and grade. All acute phase reactants separately were found to be significant prognostic factors of survival using the log rank test. However, when a multivariate Cox analysis was performed, only stage, grade, and ESR were identified as independent prognostic factors, whereas the other factors were not.
CONCLUSIONS: The study suggests that all acute phase reactants separately were found to be significant univariate prognostic factors, but in a multivariate analysis, ESR was the only independent prognostic parameter for survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8620420     DOI: 10.1002/1097-0142(19951015)76:8<1435::aid-cncr2820760821>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Prognostic factors in renal cell carcinoma.

Authors:  Börje Ljungberg
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  Haptoglobin-related protein as a serum marker in malignant lymphoma.

Authors:  R Epelbaum; C Shalitin; R Segal; C Valansi; I Arselan; D Faraggi; M Leviov; M Ben-Shahar; N Haim
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

Authors:  Xiang Chen; JiaXi Yao; Li Liu; WenZhong Zheng; XiaoYi Hu; YanJun Zhu; Hang Wang; JianMing Guo
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

4.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Authors:  H Allgayer; R Babic; K U Grützner; B C Beyer; A Tarabichi; F W Schildberg; M M Heiss
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

Review 5.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

6.  The longitudinal relationship between circulating concentrations of C-reactive protein, interleukin-6 and interleukin-10 in patients undergoing resection for renal cancer.

Authors:  S Ramsey; G W A Lamb; M Aitchison; D C McMillan
Journal:  Br J Cancer       Date:  2006-09-26       Impact factor: 7.640

7.  Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable.

Authors:  U M Vogl; H Zehetgruber; M Dominkus; M Hejna; C C Zielinski; A Haitel; M Schmidinger
Journal:  Br J Cancer       Date:  2006-08-29       Impact factor: 7.640

8.  Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma.

Authors:  R Hoffmann; A Franzke; J Buer; S Sel; K Oevermann; A Duensing; M Probst; S Duensing; H Kirchner; A Ganser; J Atzpodien
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 9.  Novel concepts in the staging of renal cell carcinoma.

Authors:  Dan Leibovici; Arie Lindner; Avishay Sella; Amnon Zisman
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

10.  The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer.

Authors:  E Bromwich; D C McMillan; G W A Lamb; P A Vasey; M Aitchison
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.